MedTrace Logo

Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia

NCT01467661 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2021-06-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to provide SPD422 to subjects who completed Study SPD422 308 and, in the opinion of the Investigator, will continue to benefit from treatment.

Conditions

  • Essential Thrombocythemia (ET)

Interventions

DRUG

SPD422 (anagrelide hydrochloride)

Subjects will be continued on the dose of anagrelide that controlled their platelet levels in Study 308 and titrated if necessary.

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-27
Primary Completion
2015-05-01
Completion
2015-05-01

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01467661 on ClinicalTrials.gov